CorVel's Q3 Net Income Jumps 19% on Strong Revenue Growth

TL;DR

**CRVL is a buy; strong earnings and cash flow indicate robust operational health and future growth potential.**

AI Summary

CORVEL CORP (CRVL) reported a strong financial performance for the three and six months ended September 30, 2025. For the three-month period, revenues increased by 6.8% to $239,643,000 from $224,380,000 in the prior year, driven by growth in both patient management and network solutions services. Net income for the quarter rose significantly by 19.3% to $27,906,000, up from $23,398,000. Diluted EPS also saw a healthy increase to $0.54 from $0.45. Over the six-month period, revenues climbed 8.8% to $474,354,000 from $436,102,000, and net income surged by 22.6% to $55,141,000 compared to $44,975,000 in the same period last year. Diluted EPS for the six months reached $1.06, up from $0.87. The company's cash and cash equivalents increased to $207,453,000 as of September 30, 2025, from $170,584,000 at March 31, 2025, reflecting robust cash flow from operations of $80,035,000 for the six months. A three-for-one forward stock split was effected on December 24, 2024, and the number of authorized shares increased to 360,000,000.

Why It Matters

CorVel's impressive revenue and net income growth signals strong demand for its managed care services, which is crucial for investors looking for stable, growing healthcare-adjacent companies. This performance could attract more institutional investors and potentially drive up CRVL's stock price, benefiting existing shareholders. For employees, continued growth often translates to job security and potential expansion opportunities. Customers, including those in workers' compensation and accident/health claims, benefit from CorVel's expanding network solutions and patient management services, which aim to optimize costs and care. In a competitive landscape, CorVel's ability to consistently grow revenues and profitability, especially with a significant increase in cash, positions it favorably against rivals in the managed care and claims administration sector.

Risk Assessment

Risk Level: low — The company demonstrates a low risk profile, evidenced by a substantial increase in cash and cash equivalents to $207,453,000 from $170,584,000, and strong net cash provided by operating activities of $80,035,000 for the six months ended September 30, 2025. This financial strength provides a buffer against unforeseen challenges and supports continued investment and shareholder returns.

Analyst Insight

Investors should consider increasing their position in CRVL, given the strong financial performance, significant cash generation, and effective capital management through share repurchases. The consistent growth in both revenue and net income suggests a well-managed company with a solid market position.

Financial Highlights

revenue

$239,643,000

net Income

$27,906,000

eps

$0.54

cash Position

$207,453,000

revenue Growth

+6.8%

Revenue Breakdown

Key Numbers

• $239.6M — Quarterly Revenue (Up 6.8% from $224.4M in Q3 2024)
• $27.9M — Quarterly Net Income (Increased 19.3% from $23.4M in Q3 2024)
• $0.54 — Quarterly Diluted EPS (Up from $0.45 in Q3 2024)
• $474.4M — Six-Month Revenue (Up 8.8% from $436.1M in the prior year period)
• $55.1M — Six-Month Net Income (Increased 22.6% from $45.0M in the prior year period)
• $1.06 — Six-Month Diluted EPS (Up from $0.87 in the prior year period)
• $207.5M — Cash and Cash Equivalents (Increased from $170.6M at March 31, 2025)
• $80.0M — Net Cash from Operations (For the six months ended September 30, 2025)
• 3-for-1 — Forward Stock Split (Effected on December 24, 2024)
• 51,246,949 — Shares Outstanding (As of November 3, 2025)

Key Players & Entities

• CORVEL CORP (company) — registrant
• SEC (regulator) — United States Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• $239,643,000 (dollar_amount) — revenues for three months ended September 30, 2025
• $27,906,000 (dollar_amount) — net income for three months ended September 30, 2025
• $474,354,000 (dollar_amount) — revenues for six months ended September 30, 2025
• $55,141,000 (dollar_amount) — net income for six months ended September 30, 2025
• $207,453,000 (dollar_amount) — cash and cash equivalents at September 30, 2025
• $80,035,000 (dollar_amount) — net cash provided by operating activities for six months ended September 30, 2025
• December 24, 2024 (date) — date of three-for-one forward stock split

FAQ

Risk Factors

• Healthcare Regulatory Changes [medium — regulatory]: Changes in healthcare laws and regulations, including those related to reimbursement, patient privacy (HIPAA), and healthcare reform, could adversely affect the Company's operations and financial results. Compliance with these evolving regulations requires ongoing investment and vigilance.
• Competition and Market Saturation [medium — market]: The healthcare services market is competitive, with numerous established players and new entrants. Increased competition could lead to pricing pressures, reduced market share, and impact revenue growth. The Company faces competition from other third-party administrators and healthcare management companies.
• Technology and Data Security [high — operational]: The Company relies heavily on its technology infrastructure and the secure handling of sensitive patient data. Any disruption to its IT systems or a breach of data security could result in significant financial losses, reputational damage, and regulatory penalties.
• Economic Downturn Impact [low — financial]: A significant economic downturn could reduce healthcare spending by employers and individuals, impacting demand for the Company's services. This could lead to lower revenues and profitability.
• Litigation and Legal Claims [medium — legal]: The Company is subject to various legal proceedings and claims incidental to its business. Adverse outcomes in litigation could result in substantial monetary damages and negatively impact financial condition.

Industry Context

CorVel operates in the healthcare services sector, specifically focusing on claims management, utilization review, and network solutions, primarily for workers' compensation and auto insurance. The industry is characterized by increasing complexity in healthcare regulations, a growing emphasis on cost containment, and the adoption of technology to improve efficiency and patient outcomes. Key trends include the shift towards value-based care and the use of data analytics to manage risk and optimize provider networks.

Regulatory Implications

The healthcare industry is heavily regulated. CorVel must navigate complex compliance requirements related to patient privacy (HIPAA), billing practices, and state-specific insurance regulations. Changes in healthcare policy or enforcement actions could significantly impact operations and profitability, necessitating continuous adaptation and investment in compliance measures.

What Investors Should Do

1. Monitor revenue growth drivers
2. Analyze operating margin trends
3. Evaluate cash flow generation
4. Assess impact of stock split

Key Dates

• 2025-09-30: End of Second Fiscal Quarter — Reporting period for the 10-Q, showing strong revenue and net income growth.
• 2025-03-31: End of Fiscal Year / Prior Period Balance Sheet Date — Comparison point for cash and cash equivalents, showing an increase to $207.5M from $170.6M.
• 2024-12-24: Forward Stock Split — A 3-for-1 stock split was effected, impacting share counts and EPS calculations for prior periods.
• 2025-05-23: Filing of 2025 Annual Report on Form 10-K — Provides audited financial statements for the fiscal year ended March 31, 2025, serving as a reference for the current interim statements.
• 2025-11-03: Shares Outstanding Reporting Date — Reported 51,246,949 shares outstanding as of this date, post-stock split.

Glossary

Forward Stock Split

An action taken by a company to increase the number of its outstanding shares by dividing each existing share into multiple new shares. This reduces the per-share price but does not change the company's total market capitalization. (CorVel effected a 3-for-1 forward stock split on December 24, 2024, requiring retroactive adjustment of historical per-share data.)

Diluted EPS

Earnings Per Share (EPS) calculated by dividing net income by the total number of diluted shares outstanding. Diluted shares include common stock equivalents like stock options and convertible securities. (Indicates the company's profitability on a per-share basis, accounting for potential dilution from outstanding securities. Increased to $0.54 for the quarter.)

Cash and Cash Equivalents

Includes cash on hand, bank deposits, and short-term, highly liquid investments with original maturities of three months or less. (Represents the most liquid assets available to the company, crucial for short-term obligations and operational flexibility. Increased to $207.5M.)

Net Cash from Operations

The cash generated or used by a company's normal business operations over a period. It excludes cash flows from investing and financing activities. (A key indicator of a company's ability to generate cash internally to fund its operations, pay debts, and invest in its business. Reported at $80.0M for six months.)

Patient Management Services

Services provided to manage patient care, including claims processing, utilization review, and case management, often for workers' compensation or health insurance. (A core revenue-generating segment for CorVel, showing growth in the reported periods.)

Network Solutions Services

Services related to managing and optimizing a network of healthcare providers, facilities, and vendors to deliver cost-effective care. (Another key revenue segment for CorVel, contributing to the overall top-line growth.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, CorVel has demonstrated significant financial improvement. For the three months ended September 30, 2025, revenue increased by 6.8% and net income surged by 19.3%, leading to a substantial rise in diluted EPS from $0.45 to $0.54. The six-month period showed even stronger growth, with revenues up 8.8% and net income climbing 22.6%, pushing diluted EPS from $0.87 to $1.06. The company also strengthened its balance sheet, increasing cash and cash equivalents by over $36 million from the end of the fiscal year. No new significant risks were highlighted in this excerpt compared to general industry and operational risks previously identified.

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share CRVL The Nasdaq Global Se

Filing Documents

• crvl-20250930.htm (10-Q) — 2181KB
• crvl-ex31_1.htm (EX-31.1) — 11KB
• crvl-ex31_2.htm (EX-31.2) — 11KB
• crvl-ex32_1.htm (EX-32.1) — 8KB
• crvl-ex32_2.htm (EX-32.2) — 8KB
• 0001193125-25-269721.txt ( ) — 8190KB
• crvl-20250930.xsd (EX-101.SCH) — 800KB
• crvl-20250930_htm.xml (XML) — 1724KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Consolidated Balance Sheets – September 30, 2025 (unaudited) and March 31, 2025 3 Consolidated Income Statements (unaudited) – Three months ended September 30, 2025 and 2024 4 Consolidated Income Statements (unaudited) – Six months ended September 30, 2025 and 2024 5 Consolidated Statements of Stockholders' Equity (unaudited) – Three and six months ended September 30, 2025 and 202 4 6 Consolidated Statements of Cash Flows (unaudited) – Six months ended September 30, 2025 and 2024 7

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 3. Defaults Upon Senior Securities 36 Item 4. Mine Safety Disclosures 36 Item 5. Other Information 36 Item 6. Exhibits 37

Signatures

Signatures 38 Page 2

– FINANC IAL INFORMATION

PART I – FINANC IAL INFORMATION

– F I NANCIAL STATEMENTS

ITEM 1 – F I NANCIAL STATEMENTS CORVEL CORPORATION Consolidated B alance Sheets September 30, 2025 March 31, 2025 (Unaudited) Assets Current Assets Cash and cash equivalents $ 207,453,000 $ 170,584,000 Customer deposits 112,302,000 101,472,000 Accounts receivable, net 104,919,000 104,126,000 Prepaid taxes and expenses 9,593,000 10,507,000 Total current assets 434,267,000 386,689,000 Property and equipment, net 111,174,000 92,052,000 Goodwill 36,814,000 36,814,000 Other intangibles, net 350,000 438,000 Right-of-use asset, net 19,178,000 20,825,000 Deferred tax asset, net 9,408,000 8,704,000 Other assets 490,000 454,000 TOTAL ASSETS $ 611,681,000 $ 545,976,000 Liabilities and Stockholders' Equity Current Liabilities Accounts and taxes payable $ 23,110,000 $ 16,792,000 Accrued liabilities 207,219,000 187,244,000 Total current liabilities 230,329,000 204,036,000 Long-term lease liabilities 18,575,000 19,953,000 Total liabilities 248,904,000 223,989,000 Commitments and contingencies Stockholders' Equity Common stock, $ .0001 par value: 360,000,000 shares authorized at September 30, 2025 and March 31, 2025; 166,000,944 shares issued ( 51,293,374 shares outstanding, net of Treasury shares) and 165,836,235 shares issued ( 51,359,544 shares outstanding, net of Treasury shares) at September 30, 2025 and March 31, 2025, respectively 5,000 5,000 Paid-in capital 258,511,000 250,407,000 Treasury stock ( 114,707,570 shares at September 30, 2025 and 114,476,691 shares at March 31, 2025) ( 853,965,000 ) ( 831,510,000 ) Retained earnings 958,226,000 903,085,000 Total stockholders' equity 362,777,000 321,987,000 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 611,681,000 $ 545,976,000 See accompanying notes to unaudited consolidated financial statements. Page 3 CORVEL CORPORATION Consolidated Income S

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements September 30, 2025 Note 1 — Summary of Significant Accounting Policies Basis of Presentation: The unaudited consolidated financial statements include the accounts of CorVel Corporation (the "Company," "we", "our", or "us") and its consolidated subsidiaries. Significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements herein have been prepared by the Company pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The accompanying interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended March 31, 2025. Accordingly, note disclosures which would substantially duplicate the disclosures contained in the March 31, 2025 audited consolidated financial statements have been omitted from these interim unaudited consolidated financial statements. The Company evaluated all subsequent events and transactions through the date of filing this report. Certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three and six months ended September 30, 2025, are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2026 or any other period. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended March 31, 2025, included in the Company's Annual Report on Form 10-K filed with the SEC on May

View Full Filing

View this 10-Q filing on SEC EDGAR